OR WAIT null SECS
The companies have signed an agreement for the production of two plasmids needed for the manufacture of CG01, a gene therapy for the treatment of drug-resistant focal epilepsy.
Cobra Biologics, a contract development and manufacturing organization (CDMO), announced on Sept. 10, 2020 that it has signed an agreement with CombiGene, a gene therapy company located in Sweden, for the good manufacturing practice (GMP) production of two plasmids needed for the manufacture of CG01, a gene therapy for the treatment of drug-resistant focal epilepsy.
Recently, Cobra completed the GMP master cell banks to produce three plasmids used as starting material for CG01, a Cobra press release said. The new agreement will help prepare the gene therapy for upcoming clinical studies.
“The fact that CombiGene has now signed an agreement with Cobra regarding the production of two plasmids is very positive as we thus secure access to crucial components for the production of CG01,” Jan Nilsson, CEO, CombiGene, in the press release. “Cobra has consistently delivered in terms of both time and quality and it is therefore very satisfactory that they will now be responsible for the production of this important part in the production of CG01. Through this agreement with Cobra, we are taking another step closer to clinical studies.”
“We are excited to continue the journey with CombiGene and this agreement is the next big step in the production of CG01,” added Peter Coleman, CEO, Cobra Biologics, in the press release. “We have a well-established plasmid production platform and in-house expertise in quality control that will ensure the delivery of GMP quality plasmid.”